These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 38824414)

  • 1. Lost in the plot: missing visual elements in Kaplan-Meier plots of phase III oncology trials.
    Sherry AD; Msaouel P; Kouzy R; Abi Jaoude J; Lin TA; Taniguchi CM; Fuller CD; Minsky B; Ludmir EB
    Oncologist; 2024 Jul; 29(7):547-550. PubMed ID: 38824414
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential Treatment Effects of Subgroup Analyses in Phase 3 Oncology Trials From 2004 to 2020.
    Sherry AD; Hahn AW; McCaw ZR; Abi Jaoude J; Kouzy R; Lin TA; Minsky B; Fuller CD; Meirson T; Msaouel P; Ludmir EB
    JAMA Netw Open; 2024 Mar; 7(3):e243379. PubMed ID: 38546648
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Empirical power comparison of statistical tests in contemporary phase III randomized controlled trials with time-to-event outcomes in oncology.
    Horiguchi M; Hassett MJ; Uno H
    Clin Trials; 2020 Dec; 17(6):597-606. PubMed ID: 32933339
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Self-reported conflicts of interest of authors, trial sponsorship, and the interpretation of editorials and related phase III trials in oncology.
    Bariani GM; de Celis Ferrari AC; Hoff PM; Krzyzanowska MK; Riechelmann RP
    J Clin Oncol; 2013 Jun; 31(18):2289-95. PubMed ID: 23630201
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Deficiencies in health-related quality-of-life assessment and reporting: a systematic review of oncology randomized phase III trials published between 2012 and 2016.
    Marandino L; La Salvia A; Sonetto C; De Luca E; Pignataro D; Zichi C; Di Stefano RF; Ghisoni E; Lombardi P; Mariniello A; Reale ML; Trevisi E; Leone G; Muratori L; Marcato M; Bironzo P; Novello S; Aglietta M; Scagliotti GV; Perrone F; Di Maio M
    Ann Oncol; 2018 Dec; 29(12):2288-2295. PubMed ID: 30304498
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Deviation from the Proportional Hazards Assumption in Randomized Phase 3 Clinical Trials in Oncology: Prevalence, Associated Factors, and Implications.
    Rahman R; Fell G; Ventz S; Arfé A; Vanderbeek AM; Trippa L; Alexander BM
    Clin Cancer Res; 2019 Nov; 25(21):6339-6345. PubMed ID: 31345838
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Censored patients in Kaplan-Meier plots of cancer drugs: An empirical analysis of data sharing.
    Rosen K; Prasad V; Chen EY
    Eur J Cancer; 2020 Dec; 141():152-161. PubMed ID: 33160265
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Surrogate endpoints].
    Hill C
    Bull Cancer; 1999; 86(7-8):622-4. PubMed ID: 10477379
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Secondary Endpoint Utilization and Publication Rate among Phase III Oncology Trials.
    Beck EJ; Sherry AD; Florez MA; Kouzy R; Abi Jaoude J; Lin TA; Miller AM; Passy AH; Kupferman GS; Patel RR; Chino F; Higbie VS; Parseghian CM; Overman MJ; Minsky BD; Thomas CR; Tang C; Msaouel P; Ludmir EB
    Cancer Res Commun; 2024 Aug; 4(8):2183-2188. PubMed ID: 39099199
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estimating hazard ratios from published Kaplan-Meier survival curves: A methods validation study.
    Saluja R; Cheng S; Delos Santos KA; Chan KKW
    Res Synth Methods; 2019 Sep; 10(3):465-475. PubMed ID: 31134735
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improving the clinical meaning of surrogate endpoints: An empirical assessment of clinical progression in phase III oncology trials.
    Sherry AD; Lin TA; McCaw ZR; Beck EJ; Kouzy R; Abi Jaoude J; Passy AH; Miller AM; Kupferman GS; Fuller CD; Thomas CR; Koay EJ; Tang C; Msaouel P; Ludmir EB
    Int J Cancer; 2024 Dec; 155(11):1939-1943. PubMed ID: 39138841
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The influence of industry sponsorship on the reporting of subgroup analyses within phase III randomised controlled trials in gastrointestinal oncology.
    Barton S; Peckitt C; Sclafani F; Cunningham D; Chau I
    Eur J Cancer; 2015 Dec; 51(18):2732-9. PubMed ID: 26608121
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discrepancies in endpoints between clinical trial protocols and clinical trial registration in randomized trials in oncology.
    Serpas VJ; Raghav KP; Halperin DM; Yao J; Overman MJ
    BMC Med Res Methodol; 2018 Dec; 18(1):169. PubMed ID: 30541475
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proportional Hazards Violations in Phase III Cancer Clinical Trials: A Potential Source of Trial Misinterpretation.
    Lin TA; McCaw ZR; Koong A; Lin C; Abi Jaoude J; Patel R; Kouzy R; El Alam MB; Sherry AD; Noticewala SS; Fuller CD; Thomas CR; Sun R; Lee JJ; Lin R; Yuan Y; Shyr Y; Meirson T; Ludmir EB
    Clin Cancer Res; 2024 Oct; 30(20):4791-4799. PubMed ID: 39133081
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of differential censoring with survival and suboptimal control arms among oncology clinical trials.
    Hsu EJ; Lin TA; Dabush DR; McCaw Z; Koong A; Lin C; Abi Jaoude J; Patel R; Kouzy R; El Alam MB; Noticewala S; Yang Y; Sherry AD; Fuller CD; Thomas CR; Tang C; Msaouel P; Das P; Huang B; Tian L; Sun R; Lee JJ; Meirson T; Ludmir EB
    J Natl Cancer Inst; 2024 Jun; 116(6):990-994. PubMed ID: 38331394
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increasing Power in Phase III Oncology Trials With Multivariable Regression: An Empirical Assessment of 535 Primary End Point Analyses.
    Sherry AD; Passy AH; McCaw ZR; Abi Jaoude J; Lin TA; Kouzy R; Miller AM; Kupferman GS; Beck EJ; Msaouel P; Ludmir EB
    JCO Clin Cancer Inform; 2024 Sep; 8():e2400102. PubMed ID: 39213473
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Statistical controversies in clinical research: comparison of primary outcomes in protocols, public clinical-trial registries and publications: the example of oncology trials.
    Perlmutter AS; Tran VT; Dechartres A; Ravaud P
    Ann Oncol; 2017 Apr; 28(4):688-695. PubMed ID: 28011448
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evidenced-Based Prior for Estimating the Treatment Effect of Phase III Randomized Trials in Oncology.
    Sherry AD; Msaouel P; Kupferman GS; Lin TA; Abi Jaoude J; Kouzy R; McCaw ZR; Ludmir EB; van Zwet E
    JCO Precis Oncol; 2024 Oct; 8():e2400363. PubMed ID: 39348660
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proposals on Kaplan-Meier plots in medical research and a survey of stakeholder views: KMunicate.
    Morris TP; Jarvis CI; Cragg W; Phillips PPJ; Choodari-Oskooei B; Sydes MR
    BMJ Open; 2019 Sep; 9(9):e030215. PubMed ID: 31575572
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.